Peptide Synthesis Market

Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method (Chemical Synthesis and Non-Chemical Synthesis), Type of Chemical Synthesis (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis and Hybrid Phase Peptide Synthesis), Contract Manufacturing Organization Size (Small, Mid-sized, and Large Companies), Key Geographical Regions (North America, Europe, and Asia-Pacific and Rest of the World)

  • Lowest Price Guaranteed From USD 4,799

  • Pages
    390

  • View Count
    30267

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Considerations
2.6.1. Demographics
2.6.2. Economic Factors
2.6.3. Government Regulations
2.6.4. Supply Chain
2.6.5. COVID Impact / Related Factors
2.6.6. Market Access
2.6.7. Healthcare Policies
2.6.8. Industry Consolidation

2.7. Key Market Segmentations

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates

3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Peptides
5.2.1. Structural Analysis of Peptides
5.2.2. Classification of Peptides
5.2.3. Peptide Synthesis
5.2.4. Emerging Technologies for Peptide Synthesis

5.2.5. Peptide Modification
5.2.5.1. N-terminal Modification
5.2.5.2. Internal Modification
5.2.5.3. C-terminal Modification
5.2.5.4. Other Modifications

5.2.6. Peptide Purification
5.2.6.1. Peptide Purity Guidelines

5.3. Overview of Contract Manufacturing
5.3.1. Need for Outsourcing in the Peptide Manufacturing Industry
5.3.2. General Considerations for Selecting a CMO Partner
5.3.3. Advantages of Outsourcing Manufacturing Operations
5.3.4. Risks and Challenges Associated with Outsourcing of Peptide API Manufacturing

5.4. Future Perspectives

6. REGULATORY LANDSCAPE
6.1. Chapter Overview
6.2. Regulatory Scenario: North America
6.2.1. Scenario in The US
6.2.1.1. Overview
6.2.1.2. General Guidelines for Peptide Manufacturing

6.3. Regulatory Scenario: Europe
6.3.1. Scenario in Europe
6.3.1.1. Overview
6.3.1.2. General Guidelines

6.3.2. Scenario in The UK
6.3.2.1. Overview
6.3.2.2. General Guidelines for Peptide Manufacturing

6.4. Regulatory Scenario: Asia-Pacific
6.4.1. Overview
6.4.2. Scenario in Australian
6.4.2.1. General Guidelines for Peptide Manufacturing

6.4.3. Scenario in Chinese
6.4.3.1. General Guidelines for Peptide Manufacturing
6.4.3.2. Tax-related Modifications in Chinese Pharmaceutical Sector

6.4.4. Scenario in India
6.4.4.1. General Guidelines for Peptide Manufacturing
6.4.4.2. Tax-related Modifications in Indian Pharmaceutical Sector

6.4.5. Scenario in Japan
6.4.5.1. General Guidelines for Peptide Manufacturing

6.4.6. Scenario in South Korea
6.4.6.1. General Guidelines for Peptide Manufacturing

6.5. Challenges Associated with Peptide Manufacturing

7. MARKET LANDSCAPE
7.1 Chapter Overview
7.2 Peptide Therapeutics Contract API Manufacturing: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Year of Entrance of Peptide API Contract Manufacturers
7.2.3. Analysis by Company Size
7.2.4. Analysis by Location of Headquarters
7.2.5. Analysis by Type of Product
7.2.6. Analysis by Type of API Manufactured
7.2.7. Analysis by Scale of Operation
7.2.8. Analysis by Type of Services Offered
7.2.9. Analysis by Type of Peptide Synthesis Method
7.2.10. Analysis by Type of Peptide Modification
7.2.11. Analysis by Type of Purification Technology Used
7.2.12. Analysis by Regulatory Certifications and Accreditations
7.2.13. Analysis by Geographical Presence
7.2.14. Analysis by Location of Peptide API Manufacturing Facilities

7.3. List of Custom Peptide Manufacturers

8. COMPANY COMPETITIVENSS ANALYSIS
8.1. Chapter Overview
8.2. Key Parameters
8.3. Methodology
8.4. Company Competitiveness Analysis
8.4.1 Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity
8.4.2 Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity
8.4.2 Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity

9. COMPANY PROFILES
9.1 Chapter Overview
9.2. Peptide Therapeutics Contract API Manufacturers based in North America
9.2.1. AmbioPharm
9.2.1.1. Company Overview
9.2.1.2. Service Portfolio
9.2.1.3. Manufacturing Facilities and Capabilities
9.2.1.4. Recent Developments and Future Outlook

9.2.2. CPC Scientific
9.2.2.1. Company Overview
9.2.2.2. Service Portfolio
9.2.2.3. Manufacturing Facilities and Capabilities
9.2.2.4. Recent Developments and Future Outlook

9.2.3. Creative Peptides
9.2.3.1. Company Overview
9.2.3.2. Service Portfolio
9.2.3.3. Manufacturing Facilities and Capabilities
9.2.3.4. Recent Developments and Future Outlook

9.2.4. CSBio
9.2.4.1. Company Overview
9.2.4.2. Service Portfolio
9.2.4.3. Manufacturing Facilities andCapabilities
9.2.4.4. Recent Developments and Future Outlook

9.3. Peptide Therapeutics Contract API Manufacturers based in Europe
9.3.1. Bachem
9.3.1.1. Company Overview
9.3.1.2. Service Portfolio
9.3.1.3. Manufacturing Facility and Capabilities
9.3.1.4. Recent Developments and Future Outlook

9.3.2. BCN Peptides
9.3.2.1. Company Overview
9.3.2.2. Service Portfolio
9.3.2.3. Manufacturing Facility andCapabilities
9.3.2.4. Recent Development and Future Outlook

9.3.3. CordenPharma
9.3.3.1. Company Overview
9.3.3.2. Service Portfolio
9.3.3.3. Manufacturing Facility and Capabilities
9.3.3.4. Recent Developments and Future Outlook

9.3.4. PolyPeptide
9.3.4.1. Company Overview
9.3.4.2. Service Portfolio
9.3.4.3. Manufacturing Facilities and Capabilities
9.3.4.4. Recent Developments and Future Outlook

9.3.5. Senn Chemicals
9.3.5.1. Company Overview
9.3.5.2. Service Portfolio
9.3.5.3. Manufacturing Facilities and Capabilities
9.3.5.4. Recent Developments and Future Outlook

9.4. Peptide Therapeutics Contract API Manufacturers based in Asia-Pacific
9.4.1. Auspep
9.4.1.1. Company Overview
9.4.1.2. Service Portfolio
9.4.1.3. Manufacturing Facilities and Capabilities
9.4.1.4. Recent Developments and Future Outlook

9.4.2. Chinese Peptide
9.4.2.1. Company Overview
9.4.2.2. Service Portfolio
9.4.2.3. Manufacturing Facilities and Capabilities
9.4.2.4. Recent Developments and Future Outlook

9.4.3. Hybio Pharmaceutical
9.4.3.1. Company Overview
9.4.3.2. Service Portfolio
9.4.3.3. Manufacturing Facilities and Capabilities
9.4.3.4. Recent Developments and Future Outlook

9.4.4. Peptide Institute
9.4.4.1. Company Overview
9.4.4.2. Service Portfolio
9.4.4.3. Manufacturing Facilities and Capabilities
9.4.4.4. Recent Developments and Future Outlook

9.4.5. ScinoPharm
9.4.5.1. Company Overview
9.4.5.2. Service Portfolio
9.4.5.3. Manufacturing Facilities and Capabilities
9.4.5.4. Recent Developments and Future Outlook

10. RECENT DEVELOPMENTS AND INITIATIVES
10.1. Chapter Overview
10.2. Partnerships and Collaborations
10.2.1. Partnerships Models
10.2.2. List of Partnerships and Collaborations
10.2.3. Analysis by Year of Partnership
10.2.4. Analysis by Type of Partnership
10.2.5. Analysis by Year and Type of Partnership
10.2.6. Analysis by Company Size and Type of Partnership
10.2.7. Analysis by Scale of Operation
10.2.8. Analysis by Scale of Operation and Type of Partnership
10.2.9. Analysis by Green Chemistry Integration
10.2.10. Most Active Players: Analysis by Number of Partnerships

10.2.11. Analysis by Geography
10.2.11.1. Intercontinental and Intracontinental Agreements
10.2.12.2. Local and International Agreements

10.3. Recent Expansion Models
10.3.1. Expansion Models
10.3.2 List of Recent Expansions
10.3.3. Analysis by Year of Expansion
10.3.4. Analysis by Type of Expansion
10.3.5. Analysis by Year and Type of Expansion
10.3.6. Analysis by Location of Expanded Facility (Region)
10.3.7. Analysis by Location of Expanded Facility (Country)
10.3.8. Recent Expansions: Analysis by Location of Expanded Facility and Type of Expansion
10.3.9. Most Active Players: Analysis by Number of Expansions
10.3.10. Recent Expansions: Analysis by Geography (Country)
10.3.11. Recent Expansions: List of Planned Expansions

10.4. Emerging Peptide Synthesis Technologies
10.4.1. Chemo-Enzymatic Peptide Synthesis Technology
10.4.2. Continuous Flow Technology
10.4.3. Green Chemistry

11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Peptide Therapeutics: Clinical Trials Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Number of Patients Enrolled
11.3.3. Analysis by Trial Phase
11.3.4. Analysis by Trial Registration Year and Trial Phase
11.3.5. Analysis by Trial Phase and Patients Enrolled
11.3.6. Analysis by Trial Status
11.3.7. Analysis by Trial Registration Year and Trial Status
11.3.8. Analysis by Therapeutic Area
11.3.9. Analysis by Mechanism of Action
11.3.10. Analysis by Trial Registration Year and Mechanism of Action
11.3.11. Analysis by Type of Sponsor / Collaborator

11.3.12. Analysis by Study Design
11.3.12.1. Analysis by Type of Patient Allocation Model Used
11.3.12.2. Analysis by Type of Trial Masking Adopted
11.3.12.3. Analysis by Type of Intervention
11.3.12.4. Analysis by Trial Purpose

11.3.13. Most Active Players: Analysis by Number of Clinical Trials

11.3.14. Analysis by Geography
11.3.14.1. Analysis of Clinical Trials by Geography
11.3.14.2. Analysis of Clinical Trials by Geography and Trial Status
11.3.14.3. Analysis of Clinical Trials by Geography and Therapeutic Area
11.3.14.4. Analysis of Patients Enrolled by Geography
11.3.14.5. Analysis of Patients Enrolled by Geography and Trial Status

12. REGIONAL CAPABILITY ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Overall Landscape of Peptide Therapeutics Contract API Manufacturing Facilities
12.4. Peptide Therapeutics Contract API Manufacturing Capability in North America
12.5. Peptide Therapeutics Contract API Manufacturing Capability in Europe
12.6. Peptide Therapeutics Contract API Manufacturing Capability in Asia-Pacific

13. DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Peptide Therapeutics Contract API Manufacturing: Overall Annual Demand
13.3.1. Peptide Therapeutics Contract API Manufacturing: Clinical Demand
13.3.1.1. Clinical Demand for Peptide Therapeutics Contract API Manufacturing: Analysis by Phase of Development

13.3.2. Peptide Therapeutics Contract API Manufacturing: Commercial Outsourced Demand
13.3.2.1. Commercial Demand for Peptide Therapeutics Contract API Manufacturing: Analysis by GLP-1 Mechanism of Action

13.3.3. Peptide Therapeutics Contract API Manufacturing: Analysis by Type of Peptide API Synthesis
13.3.4. Peptide Therapeutics Contract API Manufacturing: Analysis by Geography

14. CAPACITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Peptide Therapeutics Contract API Manufacturing: Global Installed Capacity
14.3.1. Analysis by Company Size
14.3.2. Analysis by Scale of Operation
14.3.3. Analysis by Location of Manufacturing Facility
14.3.4. Analysis by Company Size and Location of Manufacturing Facility
14.3.5 Analysis by Chemical Synthesis Method

14.4. Concluding Remarks

15. LIKELY PARTNERS ANLAYSIS
15.1. Chapter Overview
15.2. Scoring Criteria and Key Assumptions
15.3. Scope and Methodology

15.4. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in North America
15.4.1. Most Likely Partners
15.4.2. Likely Partners
15.4.3. Least Likely Partners

15.5. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in Europe
15.5.1. Most Likely Partners
15.5.2. Likely Partners
15.5.3. Least Likely Partners

15.6. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in Asia Pacific and Rest of the World
15.6.1. Most Likely Partners
15.6.2. Likely Partners
15.6.3. Least Likely Partners

16. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
16.1. Chapter Overview
16.2. Assumptions and Parameter Definitions
16.3. Make versus Buy Decision Making Framework
16.3.1. Scenario 1
16.3.2. Scenario 2
16.3.3. Scenario 3
16.3.4. Scenario 4

16.4. Concluding Remarks

17. TOTAL COST OF OWNERSHIP FOR PEPTIDE CONTRACT MANUFACTURING ORGANIZATIONS
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Key Parameters
17.4. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0-Y20
17.5. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by CAPEX And OPEX, Y0 and Y20
17.5.1. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by CAPEX, Y0
17.5.2. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by OPEX, Y1-Y20

18. GLOBAL PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Global Peptide Therapeutics Contract API Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
18.3.1. Scenario Analysis
18.3.1.1. Conservative Scenario
18.3.1.2. Optimistic Scenario

18.4. Key Market Segmentations

19. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY TYPE OF PEPTIDE SYNTHESIS METHOD
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, 2023 and 2035
19.3.1. Non-chemical Synthesis Method Market: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
19.3.2. Chemical Synthesis Method Market: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
19.3.2.1 Liquid Phase Synthesis: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
19.3.2.2 Solid Phase Synthesis: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
19.3.2.3 Hybrid Phase Synthesis: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)

19.4. Data Triangulation and Validation

20. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY COMPANY SIZE
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2023 and 2035
20.3.1. Small Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
20.3.2. Mid-sized Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)
20.3.3. Large Company: Historical Trends (2021-2023) and Forecasted Estimates (2024-2035)

20.4. Data Triangulation and Validation

21. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY GEOGRAPHY
21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, 2024 and 2035
21.3.1. Peptide Therapeutics Contract API Manufacturing Market in North America: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)
21.3.1.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America
21.3.1.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America
21.3.1.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America
21.3.1.4. Peptide Therapeutics Contract API Manufacturing Market in North America for Chemical Synthesis Method
21.3.1.5. Peptide Therapeutics Contract API Manufacturing Market in North America for Non-Chemical Synthesis Method

21.3.2. Peptide Therapeutics Contract API Manufacturing Market in Europe: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)
21.3.2.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Europe
21.3.2.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Europe
21.3.2.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Europe
21.3.2.4. Peptide Therapeutics Contract API Manufacturing Market in Europe for Chemical Synthesis Method
21.3.2.5. Peptide Therapeutics Contract API Manufacturing Market in Europe for Non-Chemical Synthesis Method

21.3.3. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World: Historical Trends (2021-2024) and Forecasted Estimates (2024-2035)
21.3.3.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Asia-Pacific and Rest of the World
21.3.3.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Asia-Pacific and Rest of the World
21.3.3.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World
21.3.3.4. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method
21.3.3.5. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method

21.4. Data Triangulation and Validation

22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors
22.7. Concluding Remarks

23. CONCLUSION

24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Ascendia Pharmaceuticals
24.2.1 Company Snapshot
24.2.2. Interview Transcript: Robert Bloder (Chief Business Officer), Shaukat Ali (Senior Director of Scientific Affairs and Technical Marketing)

24.3. Almac
24.3.1 Company Snapshot
24.3.2. Interview Transcript: Alastair Hay (Vice President, Peptides)

24.4. NUMAFERM
24.4.1 Company Snapshot
24.4.2. Interview Transcript: Philipp Burling (Chief Financial Officer)

24.5. Sekisui XenoTech
24.5.1 Company Snapshot
24.5.2. Interview Transcript: Hideki Kubota (Senior Manager, Peptide Business Project Leader)

24.6. Previtalica
24.6.1 Company Snapshot
24.6.2. Interview Transcript: Sergiy Stupka (Founder and Owner)

25. APPENDIX I: TABULATED DATA

26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Overall Market Landscape
Figure 4.2 Executive Summary: Recent Developments and Initiatives
Figure 4.3 Executive Summary: Clinical Trial Analysis
Figure 4.4 Executive Summary: Demand Analysis
Figure 4.5 Executive Summary: Capacity Analysis
Figure 4.6 Executive Summary: Total Cost of Ownership
Figure 4.7 Executive Summary: Market Forecast and Opportunity Analysis (I/II)
Figure 4.7 Executive Summary: Market Forecast and Opportunity Analysis (II/II)
Figure 5.1 Methods of Peptide Synthesis
Figure 5.2 Latest Technologies for Peptide Synthesis
Figure 5.3 Peptide Modification Techniques
Figure 5.4 Types of Third-Party Service Providers
Figure 6.1 Regulatory Agencies Governing Peptide Manufacturing in the US
Figure 7.1 Peptide Therapeutics Contract API Manufacturers: Distribution by Year of Establishment
Figure 7.2 Peptide Therapeutics Contract API Manufacturers: Distribution by Year of Entrance of Peptide API Contract Manufacturers
Figure 7.3 Peptide Therapeutics Contract API Manufacturers: Distribution by Company Size
Figure 7.4 Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Headquarters
Figure 7.5 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Product
Figure 7.6 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of API Manufactured
Figure 7.7 Peptide Therapeutics Contract API Manufacturers: Distribution by Scale of Operation
Figure 7.8 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Services Offered
Figure 7.9 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Synthesis Method
Figure 7.10 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Peptide Modification
Figure 7.11 Peptide Therapeutics Contract API Manufacturers: Distribution by Type of Purification Technology Used
Figure 7.12 Peptide Therapeutics Contract API Manufacturers: Distribution by Regulatory Certifications and Accreditations
Figure 7.13 Peptide Therapeutics Contract API Manufacturers: Distribution by Geographical Presence (Region)
Figure 7.14 Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Region)
Figure 7.15 Peptide Therapeutics Contract API Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Country)
Figure 8.1 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity
Figure 8.2 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity
Figure 8.3 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity
Figure 9.1 AmbioPharm: Service Portfolio
Figure 9.2 CPC Scientific: Service Portfolio
Figure 9.3 Creative peptides: Service Portfolio
Figure 9.4 CSBio: Service Portfolio
Figure 9.5 Bachem: Service Portfolio
Figure 9.6 BCN Peptide: Service Portfolio
Figure 9.7 CordenPharma: Service Portfolio
Figure 9.8 PolyPeptide: Service Portfolio
Figure 9.9 Senn Chemicals: Service Portfolio
Figure 9.10 Auspep: Service Portfolio
Figure 9.11 Chinese Peptide: Service Portfolio
Figure 9.12 Hybio Pharmaceuticals: Service Portfolio
Figure 9.13 Peptide Institute: Service Portfolio
Figure 9.14 ScinoPharm: Service Portfolio
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wiseTrend, Pre-2019-2023
Figure 10.2 Partnerships and Collaborations: Distribution by Typeof Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Figure 10.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 10.6 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Figure 10.7 Partnerships and Collaborations: Distribution by Green Chemistry Integration
Figure 10.8 Most Active Players: Distribution by Number of Partnerships
Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 10.10 Partnerships and Collaborations: Local and International Agreements
Figure 10.11 Recent Expansions: Cumulative Year-wise Trend of Recent Expansions, Pre-2019-2023
Figure 10.12 Recent Expansions: Distribution by Type of Expansion
Figure 10.13 Recent Expansions: Distribution by Year and Type of Expansion
Figure 10.14 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Figure 10.15 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Figure 10.16 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
Figure 10.17 Most Active Players: Distribution by Number of Expansions
Figure 10.18 Recent Expansions: Distribution by Geography (Country)
Figure 10.19 Chemo-Enzymatic Peptide Synthesis Technology: Advantages and Disadvantages
Figure 10.20 Continuous Flow Technology: Advantages and Disadvantages
Figure 10.21 Green Chemistry: Advantages and Disadvantages
Figure 11.1 Clinical Trial Analysis: Scope and Methodology
Figure 11.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 11.3 Clinical Trial Analysis: Year-wise Trend of Patients Enrolled by Trial Registration Year
Figure 11.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Figure 11.6 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
Figure 11.7 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.8 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 11.9 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 11.10 Clinical Trial Analysis: Distribution by Mechanism of Action
Figure 11.11 Clinical Trial Analysis: Distribution by Trial Registration Year and Mechanism of Action
Figure 11.12 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.13 Clinical Trial Analysis: Distribution by Type of Patient Allocation Model Used
Figure 11.14 Clinical Trial Analysis: Distribution by Type of Trial Masking Adopted
Figure 11.15 Clinical Trial Analysis: Distribution by Type of Intervention
Figure 11.16 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 11.17 Most Active Industry Players: Distribution by Number of Clinical Trials
Figure 11.18 Most Active Non-industry Players: Distribution by Number of Clinical Trials
Figure 11.19 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 11.20 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
Figure 11.21 Clinical Trial Analysis: Distribution by Geography and Therapeutic Area
Figure 11.22 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 11.23 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
Figure 12.1 Regional Distribution of Peptide Therapeutics Contract API Manufacturing Facilities
Figure 12.2 Regional Capability Analysis: Peptide API Contract Manufacturers in North America
Figure 12.3 Regional Capability Analysis: Peptide API Contract Manufacturers in Europe
Figure 12.4 Regional Capability Analysis: Peptide API Contract Manufacturers in Asia-Pacific
Figure 13.1 Global Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Figure 13.2 Global Clinical Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Figure 13.3 Clinical Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Phase of Development, 2024 and 2035
Figure 13.4 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase I Trials, 2024-2035 (Kilograms)
Figure 13.5 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase II Trials, 2024-2035 (Kilograms)
Figure 13.6 Clinical Demand for Peptide Therapeutics Contract API Manufacturing for Phase III Trials, 2024-2035 (Kilograms)
Figure 13.7 Global Commercial Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Figure 13.8 Commercial Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by to GLP-1 Mechanism of Action, 2024 and 2035
Figure 13.9 Commercial Demand for Peptide Therapeutics Contract API Manufacturing forGLP-1 Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Figure 13.10 Commercial Demand for Peptide Therapeutics Contract API Manufacturing for non-GLP-1 Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Figure 13.11 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Type of Peptide Synthesis Method, 2024 and 2035 (Kilograms)
Figure 13.12 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Geography, 2024 and 2035 (Kilograms)
Figure 14.1 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size
Figure 14.2 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Range of Installed Capacity (Liters)
Figure 14.3 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Scale of Operation (Liters)
Figure 14.4 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Liters)
Figure 14.5 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size and Location of Manufacturing Facility
Figure 14.6 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Synthesis Method (Liters)
Figure 16.1 Make versus Buy Decision Making Framework
Figure 16.2 Make versus Buy Decision Making: Possible Scenario
Figure 17.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 17.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 17.3 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0-Y20 (USD Million)
Figure 17.4 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Figure 17.5 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0: Distribution by CAPEX (USD Million)
Figure 17.6 Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y1-Y20: Distribution by OPEX (USD Million)
Figure 18.1 Global Peptide Therapeutics Contract API Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 18.2 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Figure 18.3 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Figure 19.1 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, 2024 And 2035
Figure 19.2 Peptide Therapeutics Contract API Manufacturing Market for Non-chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.3 Peptide Therapeutics Contract API Manufacturing Market for Chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.4 Peptide Therapeutics Contract API Manufacturing Market for Liquid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.5 Peptide Therapeutics Contract API Manufacturing Market for Solid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 19.6 Peptide Therapeutics Contract API Manufacturing Market for Hybrid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.1 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2024 And 2035
Figure 20.2 Peptide Therapeutics Contract API Manufacturing Market for Small Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.3 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 20.4 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.1 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, 2024 And 2035
Figure 21.2 Peptide Therapeutics Contract API Manufacturing Market in North America, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.3 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America, 2024-2035 (USD Billion)
Figure 21.4 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America, 2024-2035 (USD Billion)
Figure 21.5 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America, 2024-2035 (USD Billion)
Figure 21.6 Peptide Therapeutics Contract API Manufacturing Market in North America for Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 21.7 Peptide Therapeutics Contract API Manufacturing Market in North America for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 21.8 Peptide Therapeutics Contract API Manufacturing Market in Europe, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.9 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Europe, 2024-2035 (USD Billion)
Figure 21.10 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Europe, 2024-2035 (USD Billion)
Figure 21.11 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Europe, 2024-2035 (USD Billion)
Figure 21.12 Peptide Therapeutics Contract API Manufacturing Market in Europe for Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 21.13 Peptide Therapeutics Contract API Manufacturing Market in Europe for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 21.14 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 21.15 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Figure 21.16 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Figure 21.17 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Figure 21.18 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 21.19 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Figure 22.1 Contract Peptide API Manufacturing: SWOT Analysis
Figure 22.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 23.1 Concluding Remarks: Overall Market Landscape (I/II)
Figure 23.2 Concluding Remarks: Overall Market Landscape (I/II)
Figure 23.3 Concluding Remarks: Recent Developments (I/II)
Figure 23.4 Concluding Remarks: Recent Developments (I/II)
Figure 23.5 Concluding Remarks: Clinical Trial Analysis
Figure 23.6 Concluding Remarks: Demand Analysis
Figure 23.7 Concluding Remarks: Capacity Analysis
Figure 23.8 Concluding Remarks: Likely Partner Analysis
Figure 23.9 Concluding Remarks: Total Cost of Ownership (USD Million)
Figure 23.10 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 5.1 Comparison of Major Peptide Synthesizing Processes
Table 5.2 Chromatographic Techniques
Table 6.1 Comparison of Regulatory Landscape of China and India
Table 7.1 Peptide Therapeutics Contract API Manufacturers: List of Companies
Table 7.2 Peptide Therapeutics Contract API Manufacturers: Information on Type of API and Scale of Operation
Table 7.3 Peptide Therapeutics Contract API Manufacturers: Information on Type of Services Offered and Peptide Synthesis Method
Table 7.4 Peptide Therapeutics Contract API Manufacturers: Information on Type of Peptide Modification and Type of Purification Technology Used
Table 7.5 Peptide Therapeutics Contract API Manufacturers: Information on Regulatory Certifications and Accreditations
Table 7.6 List of Custom Peptide Manufacturers
Table 8.1 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity
Table 8.2 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity
Table 8.3 Company Competitiveness Analysis: Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity
Table 9.1 Leading Peptide Therapeutics Contract API Manufacturers
Table 9.2 AmbioPharm: Company Overview
Table 9.3 AmbioPharm: Overview of Manufacturing Capabilities
Table 9.4 AmbioPharm: Recent Developments and Future Outlook
Table 9.5 CPC Scientific: Company Overview
Table 9.6 CPC Scientific: Overview of Manufacturing Capabilities
Table 9.7 CPC Scientific: Recent Developments and Future Outlook
Table 9.8 Creative Peptides: Company Overview
Table 9.9 Creative Peptides: Overview of Manufacturing Capabilities
Table 9.10 Creative Peptides: Recent Developments and Future Outlook
Table 9.11 CSBio: Company Overview
Table 9.12 CSBio: Overview of Manufacturing Capabilities
Table 9.13 CSBio: Recent Developments and Future Outlook
Table 9.14 Bachem: Company Overview
Table 9.15 Bachem: Overview of Manufacturing Capabilities
Table 9.16 Bachem: Recent Developments and Future Outlook
Table 9.17 BCN Peptides: Company Overview
Table 9.18 BCN Peptides: Overview of Manufacturing Capabilities
Table 9.19 BCN Peptides: Recent Developments and Future Outlook
Table 9.20 CordenPharma: Company Overview
Table 9.21 CordenPharma: Overview of Manufacturing Capabilities
Table 9.22 CordenPharma: Recent Developments and Future Outlook
Table 9.23 PolyPeptide: Company Overview
Table 9.24 PolyPeptide: Overview of Manufacturing Capabilities
Table 9.25 PolyPeptide: Recent Developments and Future Outlook
Table 9.26 Senn Chemicals: Company Overview
Table 9.27 Senn Chemicals: Overview of Manufacturing Capabilities
Table 9.28 Auspep: Company Overview
Table 9.29 Auspep: Overview of Manufacturing Capabilities
Table 9.30 Auspep: Recent Developments and Future Outlook
Table 9.31 Chinese Peptide: Company Overview
Table 9.32 Chinese Peptide: Overview of Manufacturing Capabilities
Table 9.33 Hybio Pharmaceuticals: Company Overview
Table 9.34 Hybio Pharmaceuticals: Overview of Manufacturing Capabilities
Table 9.35 Peptide Institute: Company Overview
Table 9.36 Peptide Institute: Overview of Manufacturing Capabilities
Table 9.37 ScinoPharm: Company Overview
Table 9.38 ScinoPharm: Overview of Manufacturing Capabilities
Table 10.1 Peptide Therapeutics Contract API Manufacturers: List of Partnerships and Collaborations, Pre-2019-2023
Table 10.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Region-wise)
Table 10.3 Peptide Therapeutics Contract API Manufacturers: List of Recent Expansions, Pre-2019-2023
Table 10.4 Peptide Therapeutics Contract API Manufacturers: List of Planned Upcoming Expansions
Table 14.1 Peptide Therapeutics Contract API Manufacturers: Information on Total Installed Capacity (Sample Dataset)
Table 14.2 Peptide Therapeutics Contract API Manufacturing: Average Capacity based on Company Size (Sample Dataset)
Table 14.3 Peptide Therapeutics Contract API Manufacturing Capacity: Average Share Based on Synthesis Method (Sample Dataset)
Table 14.4 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size (liters)
Table 15.1 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America
Table 15.2 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America
Table 15.3 Least Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in North America
Table 15.4 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe
Table 15.5 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe
Table 15.6 Least Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Europe
Table 15.7 Most Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Asia Pacific and Rest of the World
Table 15.8 Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Asia Pacific and Rest of the World
Table 15.9 Least Likely Partner Opportunities for Peptide Therapeutics Contract Manufacturers Based in Asia Pacific and Rest of the World
Table 24.1 Ascendia Pharmaceuticals: Company Snapshot
Table 24.2 Almac: Company Snapshot
Table 24.3 NUMAFERM: Company Snapshot
Table 24.4 Sekisui: Company Snapshot
Table 24.5 Previtalica: Company Snapshot
Table 25.1 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Year of Establishment
Table 25.2 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Year of Entrance
Table 25.3 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Company Size
Table 25.4 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Headquarters
Table 25.5 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Product
Table 25.6 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of API Manufactured
Table 25.7 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Scale of Operation
Table 25.8 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Service Offered
Table 25.9 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Peptide Synthesis Method
Table 25.10 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Chemical Synthesis Method
Table 25.11 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Peptide Modification
Table 25.12 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Type of Purification Technology Used
Table 25.13 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Regulatory Certifications and Accreditations
Table 25.14 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Geographical Presence (Region)
Table 25.15 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Region)
Table 25.16 Peptide Therapeutics ContractAPI Manufacturers: Distribution by Location of Peptide API Manufacturing Facilities (Country)
Table 25.17 Partnerships andCollaborations: Cumulative Year-wise Trend, Pre-2019-2023
Table 25.18 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.19 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 25.20 Partnerships and Collaborations: Distribution by Company Size and Type of Partnership
Table 25.21 Partnerships and Collaborations: Distribution by Scale of Operation
Table 25.22 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Table 25.23 Partnerships and Collaborations: Distribution by Green Chemistry Integration\
Table 25.24 Most Active Players: Distribution by Number of Partnerships
Table 25.25 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 25.26 Partnerships and Collaborations: Local and International Agreements
Table 25.27 Recent Expansions: Cumulative Year-wise Trend of Recent Expansions, Pre-2019-2023
Table 25.28 Recent Expansions: Distribution by Type of Expansion
Table 25.29 Recent Expansions: Distribution by Year and Type of Expansion
Table 25.30 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Table 25.31 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Table 25.32 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion
Table 25.33 Most Active Players: Distribution by Number of Expansions
Table 25.34 Recent Expansions: Distribution by Geography (Country)
Table 25.35 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Table 25.36 Clinical Trial Analysis: Year-wise Trend of Number of Patients Enrolled by Trial Registration Year
Table 25.37 Clinical Trial Analysis:Distribution by Trial Phase
Table 25.38 Clinical Trial Analysis:Distribution by Trial Phase and Number of Patients Enrolled
Table 25.39 Clinical Trial Analysis:Distribution by Trial Status
Table 25.40 Clinical Trial Analysis:Distribution by Trial Registration Year and Trial Status
Table 25.41 Clinical Trial Analysis:Distribution by Therapeutic Area
Table 25.42 Clinical Trial Analysis:Distribution by Mechanism of Action
Table 25.43 Clinical Trial Analysis:Distribution by Trial Registration Year and Mechanism of Action
Table 25.44 Clinical Trial Analysis:Distribution by Type of Sponsor / Collaborator
Table 25.45 Clinical Trial Analysis:Distribution by Type of Patient Allocation Model Used
Table 25.46 Clinical Trial Analysis:Distribution by Type of Trial Masking Adopted
Table 25.47 Clinical Trial Analysis:Distribution by Type of Intervention Model
Table 25.48 Clinical Trial Analysis:Distribution by Trial Purpose
Table 25.49 Most Active Industry Players:Distribution by Number of Clinical Trials
Table 25.50 Most Active Non-industryPlayers: Distribution by Number of Clinical Trials
Table 25.51 Clinical Trial Analysis:Distribution of Clinical Trials by Geography
Table 25.52 Clinical Trial Analysis:Distribution of Clinical Trials by Geography and Trial Status
Table 25.53 Clinical Trial Analysis:Distribution by Geography and Therapeutic Area
Table 25.54 Clinical Trial Analysis:Distribution of Patients Enrolled by Geography
Table 25.55 Clinical Trial Analysis:Distribution of Patients Enrolled by Geography and Trial Status
Table 25.56 Regional Distribution of Peptide Therapeutics Contract API Manufacturing Facilities
Table 25.57 Regional Capability Analysis: Regional Capability Analysis: Peptide API Contract Manufacturers in North America
Table 25.58 Regional Capability Analysis: Regional Capability Analysis: Peptide API Contract Manufacturers in Europe
Table 25.59 Regional Capability Analysis: Peptide API Contract Manufacturers in Asia Pacific and Rest of the World
Table 25.60 Global Demand for Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Table 25.61 Global Clinical Demand forPeptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Future Estimates (2024-2035) (Kilograms)
Table 25.62 Clinical Demand for PeptideTherapeutics Contract API Manufacturing: Distribution by Phase of Development, 2024 and 2035
Table 25.63 Clinical Demand for PeptideTherapeutics Contract API Manufacturing for Phase I Trials, 2024-2035 (Kilograms)
Table 25.64 Clinical Demand for PeptideTherapeutics Contract API Manufacturing for Phase II Trials, 2024-2035 (Kilograms)
Table 25.65 Clinical Demand for PeptideTherapeutics Contract API Manufacturing for Phase III Trials, 2024-2035 (Kilograms)
Table 25.66 Global Commercial Demandfor Peptide Therapeutics Contract API Manufacturing, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035) (Kilograms)
Table 25.67 Commercial Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Mechanism of Action (specific to GLP-1),
Table 25.68 Commercial Demand for Peptide Therapeutics Contract API Manufacturing for GLP-1 Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-2035)
Table 25.69 Commercial Demand for Peptide Therapeutics Contract API Manufacturing for non-GLP-1 based Drugs, Historical Trends (2017-2023) and Forecasted Estimates (2024-
Table 25.70 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Type of Peptide Synthesis Method, 2024 and 2035
Table 25.71 Global Demand for Peptide Therapeutics Contract API Manufacturing: Distribution by Geography, 2024 and 2035 (Kilograms)
Table 25.72 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size (liters)
Table 25.73 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Range of Installed Capacity (liters)
Table 25.74 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Scale of Operation (liters)
Table 25.75 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Location of Manufacturing Facility (liters)
Table 25.76 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Company Size and Location of Manufacturing
Table 25.77 Global Installed Peptide Therapeutics Contract API Manufacturing Capacity: Distribution by Synthesis Method (liters)
Table 25.78 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization, Y0-Y20 (USD Million)
Table 25.79 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Table 25.80 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization, Y0: Distribution by CAPEX (USD Million)
Table 25.81 Total Cost of Ownership forPeptide Therapeutics Contract API Manufacturing Organization, Y1-Y20: Distribution by OPEX (USD Million)
Table 25.82 Global Peptide TherapeuticsContract API Manufacturing Market, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 25.83 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Table 25.84 Global Peptide Therapeutics Contract API Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Table 25.85 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, 2024 And 2035
Table 25.86 Peptide Therapeutics Contract API Manufacturing Market for Type of Non-chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD
Table 25.87 Peptide Therapeutics Contract API Manufacturing Market for Type of Chemical Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.88 Peptide Therapeutics Contract API Manufacturing Market for Liquid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.89 Peptide Therapeutics Contract API Manufacturing Market for Solid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.90 Peptide Therapeutics Contract API Manufacturing Market for Hybrid Phase Synthesis, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.91 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, 2024 And 2035
Table 25.92 Peptide Therapeutics Contract API Manufacturing Market for Small Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-
Table 25.93 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies, Historical Trends (2021-2023) and Forecasted Estimates
Table 25.94 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies, Historical Trends (2021-2023) and Forecasted Estimates (2024-2035) (USD
Table 25.95 Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, 2024 And 2035
Table 25.96 Peptide Therapeutics Contract API Manufacturing Market in North America, Historical Trends (2021-2024) and Forecasted Estimates (2024-
Table 25.97 Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America, 2024-2035 (USD Billion)
Table 25.98 Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America, 2024-2035 (USD Billion)
Table 25.99 Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America, 2024-2035 (USD Billion)
Table 25.100 Peptide TherapeuticsContract API Manufacturing Market in North America for Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.101 Peptide TherapeuticsContract API Manufacturing Market in North America for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.102 Peptide TherapeuticsContract API Manufacturing Market in Europe, Historical Trends (2021-2024) and Forecasted Estimates (2024-2035) (USD Billion)
Table 25.103 Peptide TherapeuticsContract API Manufacturing Market for Small Companies in Europe, 2024-2035 (USD Billion)
Table 25.104 Peptide TherapeuticsContract API Manufacturing Market for Mid-sized Companies in Europe, 2024-2035 (USD Billion)
Table 25.105 Peptide TherapeuticsContract API Manufacturing Market for Large and Very Large Companies in Europe, 2024-2035 (USD Billion)
Table 25.106 Peptide TherapeuticsContract API Manufacturing Market in Europe for Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.107 Peptide TherapeuticsContract API Manufacturing Market in Europe for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.108 Peptide TherapeuticsContract API Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (2021-2024) and Forecasted Estimates (2024-
Table 25.109 Peptide TherapeuticsContract API Manufacturing Market for Small Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Table 25.110 Peptide TherapeuticsContract API Manufacturing Market for Mid-sized Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Table 25.111 Peptide TherapeuticsContract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World, 2024-2035 (USD Billion)
Table 25.112 Peptide TherapeuticsContract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method, 2024-2035 (USD Billion)
Table 25.113 Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method, 2024-2035 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 13therapeutics
  2. 9 Meters Biopharma
  3. AAPPTec
  4. Abbiotec
  5. Abcepta
  6. Abclonal
  7. ABI Scientific
  8. ACES Pharma
  9. Acinopeptide
  10. Activotec 
  11. Adalvo
  12. Adalvo
  13. Adar Biotech
  14. Advanced Accelerator Applications
  15. Advanced ChemTech
  16. Advanced Peptides
  17. ADVANZ PHARMA
  18. Ahead Therapeutics
  19. Aileron Therapeutics
  20. Ajinomoto Bio-Pharma
  21. Akashi Therapeutics
  22. Alabiochem
  23. Allysta Pharmaceuticals
  24. Almac
  25. Alpha Diagnostic
  26. AltaBioscience
  27. Altimmune
  28. AmbioPharma
  29. American Peptide Company
  30. AminoPrimeCentral
  31. Amolyt Pharma
  32. Ampio Pharmaceuticals
  33. Amunix Pharmaceuticals
  34. Amyndas Pharmaceuticals
  35. Amytrx Therapeutics
  36. AnaSpec
  37. AnGes
  38. Anji Pharmaceuticals
  39. Antagene
  40. ANYGEN
  41. APAC Pharmaceutical
  42. Apellis Pharmaceuticals
  43. Apeptico
  44. APIM Therapeutics
  45. Apitope
  46. Aquestive Therapeutics
  47. Arch Biopartners
  48. Ardena
  49. Argenica Therapeutics
  50. Ariceum Therapeutics
  51. Ascendia Pharmaceuticals
  52. AsclepiX Therapeutics
  53. Aspen
  54. AstraZeneca
  55. Asymchem
  56. Atlantic Peptides
  57. Atox Bio
  58. Aurinia Pharmaceuticals
  59. Auspep
  60. Averica
  61. Avilex Pharma
  62. AXON Neuroscience
  63. Axplora
  64. Bachem
  65. Bayer
  66. BCN Peptides
  67. Bicycle Therapeutics
  68. Bioassay
  69. BioConcept
  70. BioLineRx
  71. Biolingus
  72. Biomarck Pharmaceuticals
  73. BioMarin Pharmaceutical
  74. Biomer Technology
  75. Biopeptek Pharmaceuticals
  76. Bioserv
  77. Biosynth
  78. Bio-Synthesis
  79. BioVectra
  80. Boehringer Ingelheim
  81. Boston Therapeutics
  82. Burrard Pharmaceuticals
  83. California Peptide 
  84. Cambridge Peptides
  85. Cambridge Research Biochemicals
  86. CanBas
  87. CanPeptide
  88. CARBOGEN AMCIS
  89. Carmot Therapeutics
  90. CASLO
  91. CBL
  92. Cellmano Biotech
  93. Celtek Peptides
  94. CEM
  95. Cend Therapeutics
  96. ChemPartner
  97. ChemPep
  98. ChinaTech Peptide
  99. Chinese Peptide Company
  100. Chondropeptix
  101. Chrysalis BioTherapeutics
  102. Clinuvel Pharmaceuticals
  103. CohBar
  104. CombiGene
  105. Constant Therapeutics
  106. CordernPharma
  107. Corvid Pharmaceuticals
  108. Covalab
  109. CPC Scientific
  110. Creative Peptides
  111. CreoSalus
  112. CSBio
  113. CureDM
  114. Curonz
  115. Curtin University
  116. Cytovation
  117. Dalton Pharma
  118. Deca Peptide
  119. Designer Bioscience
  120. Diabetology
  121. Diapin Therapeutics 
  122. Dottikon ES
  123. Dr Reddy's Laboratories
  124. Eli Lilly
  125. Entera Bio
  126. Enzene Biosciences
  127. Enzo Life Sciences
  128. EOC Pharma 
  129. Esperance Pharmaceuticals
  130. EUROAPI
  131. Eurogentec
  132. Europe Pharmaceutical
  133. F4 Pharma 
  134. FirstString Research
  135. Follicum
  136. Frontier Biotechnologies
  137. Genervon Biopharmaceuticals
  138. Genosphere
  139. Genpro Biotech
  140. GenScript Biotech
  141. Genus Oncology
  142. Gila Therapeutics
  143. GlioCure
  144. GP Pharm
  145. Institut des Biomolécules Max   Mousseron (IBMM)
  146. Grey Matter Research Foundation
  147. GYRUS Pharma
  148. Hamlet BioPharma
  149. Hemmo Pharmaceuticals
  150. HighTide Therapeutics
  151. Hybio Pharmaceutical
  152. iBio
  153. IBMM Peptide
  154. i-DNA Biotechnology 
  155. IDP Pharma
  156. ILC Therapeutics
  157. ILS 
  158. Imcyse 
  159. ImmuPharma
  160. Innovagen
  161. Inotrem
  162. Intavis Peptide Services
  163. InterK Peptide Therapeutics
  164. Iris Biotech
  165. Issar Pharmaceuticals
  166. Jitsubo
  167. JPT Peptide Technologies
  168. Kaijie Peptide
  169. Kalos Therapeutics
  170. KareBayTM Biochem
  171. Kinexus
  172. KriSan Biotech
  173. La Jolla Pharmaceutical 
  174. Lassogen
  175. LifeTein
  176. Longevity Biotech
  177. Lonza
  178. Lyotex
  179. Mayo Clinic
  180. MedImmune
  181. MElkin Pharmaceuticals
  182. MeSCue-Janusys
  183. Millennium Pharmaceuticals
  184. Mimotopes
  185. MuseChem Chemicals
  186. MYR Pharmaceuticals
  187. Nanomerics
  188. SBW Life Sciences (formerly Nanos)
  189. Natco Pharma
  190. National Cancer Institute (NCI)
  191. NervGen Pharma
  192. Neuland Laboratories
  193. Neuro-Bio
  194. New England Peptide
  195. NextPharma
  196. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  197. National Institutes of Health (NIH)
  198. NovaCell Technology
  199. Novavax
  200. Novetide
  201. Novo Nordisk
  202. NSJ Prayog Life Science
  203. NUMAFERM
  204. Odense University Hospital (OUH)
  205. Olon
  206. ONL Therapeutics
  207. OPKO Health
  208. Oramed Pharmaceuticals
  209. ORPEGEN Peptide Chemicals
  210. Otsuka Chemical
  211. Ovoca Bio
  212. Oxalo Therapeutics
  213. Oxurion
  214. Palatin Technologies
  215. Pepceuticals
  216. PEPDesign 
  217. Pepscan
  218. PEP-Therapy
  219. Peptide 2.0
  220. Peptide Institute
  221. Peptide Sciences Laboratory, University of KwaZulu-Natal (UKZN)
  222. Peptide Synthetics
  223. peptides&elephants
  224. Peptilogics
  225. PeptiStar
  226. PeptiSystems
  227. Peptron
  228. Pfanstiehl 
  229. PharmaMar
  230. Phoenix Pharmaceuticals
  231. piCHEM
  232. PIN Pharma
  233. Piramal Pharma
  234. PolyPeptide
  235. Polyphor
  236. Previtalica
  237. Priavoid
  238. PrimaPharma
  239. Primm Biotech
  240. Priveel peptides
  241. ProImmune
  242. ProLynx
  243. ProNeurogen 
  244. Protagenic Therapeutics
  245. Protagonist Therapeutics
  246. Proteimax 
  247. ProteoGenix
  248. ProvePharm
  249. Pulmotect
  250. Quantum Hi-Tech (China) Biological (acquired by Tate & Lyle)
  251. Radius Health
  252. Rani Therapeutics
  253. Recipharm
  254. RegeneRx Biopharmaceuticals
  255. Revolo Biotherapeutics
  256. Rhythm Pharmaceuticals
  257. rPeptide
  258. RS Synthesis
  259. Salix Pharmaceuticals
  260. Sanofi
  261. Santhera Pharmaceuticals
  262. Sapience Therapeutics
  263. SBS Genetech
  264. Scancell
  265. Schafer-N
  266. Scilight Biotechnology
  267. ScinoPharm 
  268. Seachaid Pharmaceuticals
  269. Sekisui Medical
  270. Senn Chemicals
  271. Serpin Pharma
  272. Severn Biotech
  273. Shengnuo Peptide
  274. Shenzhen JYMed Technology
  275. Shilpa Medicare
  276. Jiangsu Sinopep Allsino Biopharmaceutical 
  277. Smaart Pharmaceuticals
  278. Soligenix
  279. Soricimed Biopharma
  280. Space Peptides
  281. STA Pharmaceutical (a subsidiary of WuXi AppTec)
  282. Stealth BioTherapeutics
  283. Sterling Pharma Solutions 
  284. Sussex Research Laboratories
  285. Synex
  286. SYNG Pharmaceuticals
  287. Syngene
  288. Takeda Pharmaceuticals
  289. TCG Lifesciences
  290. TearSolutions
  291. The University of Adelaide, Australia
  292. TheraSource
  293. Topas Therapeutics
  294. Tufts University Core Facility
  295. TwoToBiotech
  296. UCB Pharma
  297. UNC Lineberger Comprehesive Cancer Center
  298. United Biosystems
  299. University of Colorado, Denver
  300. University of Copenhagen
  301. United States Biological
  302. USV
  303. Valliscor
  304. Vanderbilt University Medical Center
  305. Vault Pharma
  306. Vaxeal
  307. Viatem
  308. Vivtide
  309. W. R. Grace 
  310. Wilshire Technologies
  311. Wuhan Jetide Biotech
  312. Xigen
  313. XL-protein
  314. YMC
  315. Yokogawa Electric
  316. Zealand Pharma
  317. Zhangzhou Sinobioway Peptide
  318. Zhejiang Peptides Biotech
  319. Zucara Therapeuti

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com